Common Contracts
2 similar License Agreement contracts by Zenas BioPharma, Inc.
SECOND AMENDMENT TO LICENSE AGREEMENT BETWEEN XENCOR, INC. AND ZENAS BIOPHARMA, INC.License Agreement • August 22nd, 2024 • Zenas BioPharma, Inc. • Pharmaceutical preparations
This Second Amendment (this “Second Amendment”) to the License Agreement, entered into as of May 27, 2021, by and between Xencor, Inc. (“XENCOR”) and Zenas BioPharma, Inc. (formerly “Zenas Biopharma (Cayman) Limited”) (“Zenas”), as amended by the First Amendment to License Agreement between XENCOR and Zenas, entered into as of November 3, 2021 (the “Agreement”), is entered into by and between XENCOR and Zenas and made effective as of August 30, 2023 (the “Second Amendment Effective Date”). Capitalized terms used but not otherwise defined herein will have the meanings ascribed to such terms in the Agreement.
SECOND AMENDMENT TO LICENSE AGREEMENT BETWEEN XENCOR, INC. AND ZENAS BIOPHARMA, INC.License Agreement • January 25th, 2024 • Zenas BioPharma, Inc. • Pharmaceutical preparations
This Second Amendment (this “Second Amendment”) to the License Agreement, entered into as of May 27, 2021, by and between Xencor, Inc. (“XENCOR”) and Zenas BioPharma, Inc. (formerly “Zenas Biopharma (Cayman) Limited”) (“Zenas”), as amended by the First Amendment to License Agreement between XENCOR and Zenas, entered into as of November 3, 2021 (the “Agreement”), is entered into by and between XENCOR and Zenas and made effective as of August 30, 2023 (the “Second Amendment Effective Date”). Capitalized terms used but not otherwise defined herein will have the meanings ascribed to such terms in the Agreement.
